Gene Therapy product:vMCO-I

BIOLOGICAL2 trials

Sponsors

Nanoscope Therapeutics Inc.

Conditions

Retinal DegenerationRetinal DiseaseRetinal DiseasesRetinitis Pigmentosa

Phase 1

Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa

CompletedNCT04919473

Nanoscope Therapeutics Inc.Retinal Degeneration, Retinal Diseases, Retinitis Pigmentosa

Start: 2019-10-23End: 2020-10-31Updated: 2021-06-09

Unknown Phase

A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection

Enrolling by invitationNCT05921162

Nanoscope Therapeutics Inc.Retinal Degeneration, Retinal Disease, Retinitis Pigmentosa

Start: 2023-07-14End: 2025-05-31Target: 11Updated: 2025-03-25